Keeper Security: New report reveals significant cybersecurity pressures on UK businesses
9.7.2021 10:00:00 EEST | Business Wire | Press release
UK businesses are struggling to deal with multiple urgent cybersecurity challenges, new research by Keeper Security has revealed. The 2021 Cybersecurity Census Report shows cyberattacks are becoming more vicious, frequent and sophisticated, while UK businesses are underprepared and too slow to counter these attacks. As a result, senior leaders within UK organisations are preoccupied with playing a cyberattack blame game instead of investing in boosting their defences.
The report has found that more than nine in ten (92%) UK business suffered a cyberattack in the last 12 months and three quarters (78%) feel unprepared to deal with this threat. Nearly a third (31%) believe CTOs should take the blame in the case of a successful cyberattack. Such a weight of responsibility means cybersecurity standards are dropping: 36% of senior IT leaders confess to having kept a cyberattack to themselves, while 32% admit to using weak credentials such as ‘password’ or ‘admin’ to protect their data.
“UK businesses are clearly worried about their cybersecurity and, as our report has found, the challenges are manifold, affecting everything from budgets to productivity,” said Darren Guccione, CEO & co-founder, Keeper Security. “While there is a desire to boost security efforts, companies are facing many competing challenges right now and, understandably, might not always make cybersecurity investments a priority. Our report is an urgent reminder for organisations to proactively address their cybersecurity challenges as a priority since deferring them will make the consequences far more severe.”
Key findings include:
- Almost all (92%) UK organisations are aware of gaps or weak links in their cybersecurity defences are, but less than half (40%) are actively addressing all of them
- Two-thirds (66%) of UK organisations have relaxed their cybersecurity policies over the past 12 months so staff can work remotely or in order not to stifle productivity
- 58% of IT professionals feel employees at their organisations do not understand the full consequences of poor cyber-hygiene
- 61% of UK companies have a skills shortage in cybersecurity
- The financial fallout of cyberattacks has been damaging, too, costing nearly one in ten (8%) UK businesses over £1 million
- An overwhelming 87% of IT leaders support the creation of a nationwide governing body to hold businesses to account when it comes to best online security practices
- And almost all (91%) are in agreement that UK businesses should be legally required to have basic cybersecurity protections in place to be allowed to operate
“Companies are struggling to put the right solutions in place to cope with cyberattacks and the consequences are both damaging and costly,” said Craig Lurey, CTO and co-founder, Keeper Security. “The conditions caused by Covid-19 have led to an increased amount of hybrid working, making effective cybersecurity defences even harder to achieve. But if businesses want to bounce back fully after the pandemic, they must get their security hygiene in order without delay.”
Despite the rise in cyberattacks and increasing pressures felt by security teams, more than a quarter of UK companies (28%) do not consider IT to be even in their top three priorities as they plan for the next 12 months. This is particularly worrying, given almost all (92%) UK organisations know where the gaps or weak links in their cybersecurity defences are but well under half (40%) are actively addressing them.
Guccione concludes: “While this situation can't be rectified overnight, there are straightforward steps UK businesses can take to boost their cyber defences. First, organisations should do a comprehensive cybersecurity audit, looking at where the gaps lie and how they can be addressed. Next, they need to put in place a clear plan of action for how to address these challenges. Running cybersecurity training sessions to educate employees and introducing a password management platform to keep credentials safe and secure are two simple, yet highly effective actions business can take today, to be better prepared against cyberattacks tomorrow.”
+++ ENDS +++
About Keeper Security Inc.
Keeper Security, Inc. (Keeper) is the highly-rated and patented cybersecurity platform for preventing password-related data breaches and cyberthreats. Keeper’s zero-knowledge security and encryption software is trusted by millions of people and thousands of businesses across the globe to mitigate the risk of cybertheft, boost employee productivity and meet compliance standards. Keeper has been named PC Magazine’s Best Password Manager of the Year & Editors’ Choice, PCWorld’s Editors’ Choice and is the winner of four G2 Best Software Awards and the InfoSec Award for Best Product in Password Management for SMB Cybersecurity. Keeper is SOC-2 and ISO 27001 Certified and is also listed for use by the U.S. federal government through the System for Award Management (SAM). Learn more at https://keepersecurity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005049/en/
Contact information
PR contact:
Tara Geoghegan
tara.geoghegan@archetype.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
